版本:
中国

BRIEF-Heat Biologics resumes enrollment in its non-small cell lung cancer trial

Sept 14 Heat Biologics Inc

* Resumes enrollment in its non-small cell lung cancer trial evaluating HS-110 in combination with anti-PD-1 checkpoint inhibitor

* Says decision to resume trial enrollment was based on positive data reported in June Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐